Total Credits: .75 including .75 AOA Category 1-A Credit(s)
This program will expire and must be completed by 11/26/24.
Physicians and medical professionals will learn why long-term randomized clinical trials against placebo were done to verify the cardiovascular safety of novel hypoglycemic agents. They will compare and contrast outcomes in randomized clinical trials for sodium-glucose-linked transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors for cardiovascular or renal endpoints. They will be able to name the pharmacological agents (and their indications) that have received FDA approval for "benefits beyond glucose-lowering" with regard to preventing cardiovascular or renal endpoints.
Learning Objectives:
• Explain why long-term randomized clinical trials against placebo were done to verify the cardiovascular safety of novel hypoglycemic agents
• Compare and contrast outcomes in randomized clinical trials for sodium-glucose linked transporter-2 inhibitors, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors for cardiovascular or renal endpoints
• Name the pharmacological agents (and their indications) that have received FDA approval for "benefits beyond glucose-lowering" with regard to preventing cardiovascular or renal endpoints
Accreditation Statement:
The Montana Osteopathic Medical Association is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians and designates this program for a maximum of .75 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician's participation in this activity.
Planning Disclosure:
The Montana Osteopathic Medical Association Education Planning Committee has no relevant financial relationships with any organization producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients relative to the content of this presentation.
Grievance Policy:
All grievances should be in writing and should specify the nature of the grievance. Initially, all grievances should be directed to MOMA Executive Director, who will then forward said grievance to the Education & Convention Committee. All grievances will receive an initial response in writing within 30 days of receipt. If the participant does not receive a satisfactory response, then they can then submit a complaint in writing to the Bureau of Osteopathic Education of the AOA at 142 East Ontario Street, Chicago, IL 60611.
| Cardiovascular & Renal Proetection with Sodium-Glucose (2.6 MB) | 14 Pages | Available after Purchase |
William J. Elliott, M.D., Ph.D. is Professor of Preventive Medicine, Internal Medicine, and Pharmacology, Chief of the Division of Pharmacology, and Chair of The Department of Biomedical Sciences at the Pacific Northwest University of Health Sciences in Yakima, WA. After receiving the B.S. (summa cum laude) from the University of Notre Dame, he earned the M.D. and Ph.D. (in Bio-Organic Chemistry) from the University of Chicago. He trained in Internal Medicine and Pharmacology at Barnes Hospital and Washington University—St. Louis, and served as a member of the faculty of the University of Chicago from 1985-92. During the next 17 years at RUSH Medical College, he practiced, taught and did research on cardiovascular clinical pharmacology, focusing on epidemiologic studies of risk factors (including diagonal earlobe creases), laboratory investigations, federally-funded cooperative clinical trials, and many industry-supported endeavors, serving as principal investigator for about 200 clinical trials of new drugs. Dr. Elliott holds Board Certification in both Internal Medicine and Clinical Pharmacology. One of the inaugural “Specialists in Clinical Hypertension” and Fellows of the American Society of Hypertension, he contributed on five topics to JNC VI, as well as to the “long version” of JNC 7. Some of his recent publications include meta-analyses of clinical trial results, putative risk factors for cardiovascular disease, cost-containment, pharmacoeconomics, and the assessment and enhancement of medication adherence. Dr. Elliott belongs to many professional societies interested in clinical pharmacology and in hypertension, including fellowship in the American Heart Association’s High Blood Pressure Council. He has lectured on five continents, participated in the review process for many journals, societies, study sections, and funding agencies, and served as editor or co-editor for many books, monographs, and symposia. Among his honors are 29 awards for teaching excellence.
Dr. William Elliott discloses that he has author and editor relationships with Elsevier and Wolters Kluwer for which he received royalties. He discloses that he has no other relevant financial relationships with any organization producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients relative to the content of his presentation.